Athersys, Inc. (ATHX)
-NasdaqCM | Prev Close: | 1.86 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 5.67 |
|---|
| Beta: | 1.22 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.95 - 2.42 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 812,048 |
|---|
| Market Cap: | 99.43M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.51 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ATHERSYS, INC / NEW FinancialsEDGAR Online Financials(Tue, May 21)
- Wider-Than-Expected Loss at AthersysZacks(Wed, May 15)
- Athersys Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 14)
- Athersys Reports First Quarter 2013 ResultsGlobeNewswire(Tue, May 14)
- Elan in Royalty Deal with THRXZacks(Tue, May 14)
- Celgene Attains 52-Week HighZacks(Tue, May 14)
- Spectrum Pharma Reports 1Q LossZacks(Tue, May 14)
- ATHERSYS, INC / NEW Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibEDGAR Online(Tue, May 14)
- Q1 2013 Athersys, Inc. Earnings Release - After Market CloseCCBN(Tue, May 14)
- Glaxo/THRX's Breo Ellipta Gets FDA NodZacks(Mon, May 13)
- Does Cell Therapy Hold The Key To Treating Stroke?at Seeking Alpha(Mon, May 13)
- Medivation Loss Narrower Than ExpectedZacks(Mon, May 13)
- Athersys: Here’s What Investors Need to Know Before Earningsat Wall St. Cheat Sheet(Sun, May 12)
- Disappointing 1Q Earnings for IARTZacks(Fri, May 10)
- Dendreon Narrows 1Q LossZacks(Fri, May 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 15.81 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.52 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.12 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -0.13 |
|---|
Business Summary
Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The companys lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase...
View More 
0.34%